Genentech filed two supplemental biologics-license applications to the FDA to market cancer drug Avastin as a treatment for advanced breast cancer in women who have not undergone chemotherapy, parent company Roche Holding said. The applications are supported by clinical data proving Avastin effective when combined with standard chemotherapy in extending survival without disease progression.

Full Story:

Related Summaries